COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Toulsie Ramtohul(Université Paris Sciences et Lettres), Youlia Kirova(Institut Curie), Audrey Bellesœur(Hôpital Cochin), Vincent Servois(Université Paris Sciences et Lettres), Clémence Basse(Université de Versailles Saint-Quentin-en-Yvelines), Laurence Bozec(Institut Curie), Aurélien Noret(Institut Curie), Paul Cottu(Université Paris Sciences et Lettres), Enora Laas(Institut Curie), Maxime Frélaut(Institut Curie), Perrine Vuagnat(Université de Versailles Saint-Quentin-en-Yvelines), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), Delphine Héquet(Institut Curie), Xavier Paolettí(Inserm), Sarah Diakite(Institut Curie)
Cited by 125
Related Papers
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial
|The Lancet Oncology|2014|679
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Recommendations for Bowel Obstruction With Peritoneal Carcinomatosis
|Journal of Pain and Symptom Management|2014|139